Crossref
108 Real-World Comparison of sofosbuvir/velpatasvir vs. glecaprevir/pibrentasvir in an FQHC Population: Adherence and Treatment Outcomes
Journal of the American Pharmacists Association · 2026-07 · 66 (4) · 103162
DOI: 10.1016/j.japh.2026.103162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Pharmacists Association, 2026-07. Verfasst von M. Edwards.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Edwards, M. (2026). 108 Real-World Comparison of sofosbuvir/velpatasvir vs. glecaprevir/pibrentasvir in an FQHC Population: Adherence and Treatment Outcomes. Journal of the American Pharmacists Association, 66(4), 103162. https://doi.org/10.1016/j.japh.2026.103162
Vancouver
Edwards M. 108 Real-World Comparison of sofosbuvir/velpatasvir vs. glecaprevir/pibrentasvir in an FQHC Population: Adherence and Treatment Outcomes. Journal of the American Pharmacists Association. 2026;66(4):103162. doi:10.1016/j.japh.2026.103162
BibTeX
@article{Edwards2026,
author = {Edwards, M.},
title = {108 Real-World Comparison of sofosbuvir/velpatasvir vs. glecaprevir/pibrentasvir in an FQHC Population: Adherence and Treatment Outcomes},
journal = {Journal of the American Pharmacists Association},
year = {2026},
volume = {66},
number = {4},
pages = {103162},
doi = {10.1016/j.japh.2026.103162}
}
EUVIMED